<DOC>
	<DOCNO>NCT00609999</DOCNO>
	<brief_summary>Primary : To determine maximum tolerate dose &amp; dose limiting toxicity dasatinib combine w erlotinib among pt w recurrent MG Secondary : To evaluate safety &amp; tolerability dasatinib + erlotinib To evaluate pharmacokinetics dasatinib administer w erlotinib among recurrent MG pt &amp; CYP-3A enzyme induce anti-epileptic drug To evaluate anti-tumor activity regimen patient population</brief_summary>
	<brief_title>Ph I Dasatinib + Erlotinib Recurrent MG</brief_title>
	<detailed_description>Tarceva administer continuous oral dosing schedule 150 mg/day pt EIAEDs &amp; 450 mg/day pt EIAEDs . Starting dose level dasatinib 100 mg day via continuous oral daily dosing . Dasatinib increase successive cohort enrol pt . Pts remain treatment excessive toxicity , progressive disease , withdrawal consent/death . Pts confirm diagnosis recurrent/progressive WHO gr IV MG / WHO grade III MG . Phase I 3+3 dose escalation design w 2 independently escalate stratum : stratum A-pts CYP3A-enzyme induce anti-epileptic drug ; stratum B-pts EIAEDs . Assessment safety base mainly frequency adverse event , particularly adverse event lead discontinuation treatment &amp; number significant lab abnormality .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Diagnosis recurrent/progressive WHO grade IV MG WHO grade III MG. Pts prior lowgrade glioma eligible histologic assessment demonstrate transformation WHO grade III / IV MG &gt; 18 yr Karnofsky Performance Status &gt; 70 percent Pts present 1st , 2nd / 3rd relapse . Prior therapy must include external beam XRT Adequate bone marrow , liver &amp; renal function assess follow : Hemoglobin &gt; 9.0g/dl ANC &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Total bilirubin &lt; 1.5 x ULN ALT &amp; AST &lt; 2.5 x ULN INR &lt; 1.5 PT/PTT within normal limit . Pts receive anticoagulation treatment w lowmolecular weight heparin allow participate , oral warfarin permit Creatinine &lt; 1.5 x ULN Serum Na , K+ , Mg2+ , Phosphate &amp; Ca2+ &gt; LLN Interval &lt; 2 wks prior surgical resection &amp; initiation study regimen Interval &lt; 12 week completion standard , daily XRT , unless one follow occurs : new area enhancement MRI image outside XRT field ; biopsy proven recurrent tumor ; / radiographic evidence progressive tumor 2 consecutive scan &gt; 4 wks apart . Interval &lt; 4weeks prior chemotherapy unless unequivocal evidence tumor progression &amp; pt recover anticipated toxicity prior therapy Interval &lt; 4weeks prior investigational agent unless unequivocal evidence tumor progression &amp; pt recover anticipated toxicity prior therapy Signed write informed consent include HIPAA accord institutional guideline . Signed informed consent must obtain prior study specific procedure If sexually active , pt take contraceptive measure duration treatment &amp; 4 week follow discontinuation dasatinib &amp; Erlotinib . Women childbearing potential must negative serum urine pregnancy test within 72 hrs prior start study drug administration No prior dasatinib / oral EGFRinhibitor therapy Pregnancy/breast feeding History significant concurrent illness &gt; 3 prior episode progressive disease Significant cardiac disease Excessive risk bleeding define stroke &lt; 6 month , history CNS / intraocular bleed , / septic endocarditis . Concurrent severe and/or uncontrolled medical disease could compromise participation study include follow : pleural / pericardial effusion grade ; uncontrolled diabetes ; uncontrolled hypertension ; active clinically serious infection &gt; CTCAEv3 Gr2 require active intervention ; history clinicallysignificant bleed diathesis coagulopathy include platelet function disorder acquire bleed disorder within 1yr ; impairment GI function /GI disease may significantly alter absorption study regimen ; ongoing recent significant gastrointestinal bleeding Thrombolic embolic event cerebrovascular accident include transient ischemic attack &lt; 6 month Any hemorrhage/bleeding event &gt; CTCAEv3AE Gr3 within 4wks 1st dose study drug Serious nonhealing wound , ulcer , /bone fracture Major surgery , open biopsy /significant traumatic injury &lt; 4 week 1st study drug Known HIV infection/chronic Hepatitis B/C Pt &lt; 3yrs free another primary malignancy except : primary malignancy either currently clinically significant/does require active intervention . Existence malignant disease allow . Pts unwilling to/unable comply protocol include ability swallow whole pills/presence malabsorption syndrome Concurrent administration warfarin , rifampin/St . John 's Wort Subjects w hypokalemia/hypomagnesemia correct Prisoners/subjects compulsorily detain treatment either psychiatric/physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Recurrent MG</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Sprycel</keyword>
</DOC>